Akers Biosciences, Inc. (ABI) develops, manufactures, and supplies rapid, point-of-care screening and testing products designed to bring healthcare information both rapidly and directly to the patient or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. Akers has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.
The Company is incorporated in the United States in the State of New Jersey where all corporate operations currently reside. The rights of shareholders may be different from the rights of shareholders in a UK incorporated company. There are no restrictions on the trading of ABI's shares on AIM .